Oliceridine (TRV130), our lead product candidate with FDA Breakthrough Therapy Designation, is a next generation IV analgesic being studied for management of moderate-to-severe acute pain.
Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary ABLE™ platform.
October 27, 2016Trevena Announces Highlights from Recent Presentations
Copyright © Trevena, Inc.